Lilly Signs a License Agreement with Lycia to Develop Novel LYTAC Degraders

Shots:

Lycia to receive $35M up front and is also eligible to receive an additional ~$1.6B upon the achievement of milestones along with royalties on sales of the product emerges from the collaboration
Lilly will be responsible for the pre/clinical development of the product and also gets an exclusive global license to commercialize the product
The collaboration will utilize Lycia’s LYTAC platform to develop novel degraders for up to five targets to address unmet medical needs in immunology and pain

Click he r e to read full press release/ article | Ref: Eli Lilly | Image: Fox Business